These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 11743279)

  • 1. Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the followup of patients with transitional cell carcinoma of the bladder: a decision analytical approach.
    Lotan Y; Roehrborn CG
    J Urol; 2002 Jan; 167(1):75-9. PubMed ID: 11743279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic impact of tumor markers in bladder cancer surveillance.
    Hong YM; Loughlin KR
    Urology; 2008 Jan; 71(1):131-5. PubMed ID: 18242381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Should we screen for bladder cancer in a high-risk population?: A cost per life-year saved analysis.
    Lotan Y; Svatek RS; Sagalowsky AI
    Cancer; 2006 Sep; 107(5):982-90. PubMed ID: 16862567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of molecular and conventional strategies for followup of superficial bladder cancer using decision analysis.
    Nam RK; Redelmeier DA; Spiess PE; Sampson HA; Fradet Y; Jewett MA
    J Urol; 2000 Mar; 163(3):752-7. PubMed ID: 10687970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
    Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study.
    Pfister C; Chautard D; Devonec M; Perrin P; Chopin D; Rischmann P; Bouchot O; Beurton D; Coulange C; Rambeaud JJ
    J Urol; 2003 Mar; 169(3):921-4. PubMed ID: 12576813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
    Kumar A; Kumar R; Gupta NP
    Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer.
    Fernandez-Gomez J; Rodríguez-Martínez JJ; Barmadah SE; García Rodríguez J; Allende DM; Jalon A; Gonzalez R; Alvarez-Múgica M
    Eur Urol; 2007 May; 51(5):1267-74. PubMed ID: 17207912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
    J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors.
    Filbeck T; Pichlmeier U; Knuechel R; Wieland WF; Roessler W
    J Urol; 2002 Jul; 168(1):67-71. PubMed ID: 12050494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early diagnosis and monitoring of superficial transitional cell carcinoma by microsatellite analysis on urine sediment.
    Bartoletti R; Dal Canto M; Cai T; Piazzini M; Travaglini F; Gavazzi A; Rizzo M
    Oncol Rep; 2005 Mar; 13(3):531-7. PubMed ID: 15706429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Molecular markers for transitional cell carcinoma of bladder].
    Kleinmann J; Siegel YI; Zisman A
    Harefuah; 2003 Jul; 142(7):531-5, 565. PubMed ID: 12908389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-muscle-invasive bladder cancer surveillance for which cystoscopy is partly replaced by microsatellite analysis of urine: a cost-effective alternative?
    de Bekker-Grob EW; van der Aa MN; Zwarthoff EC; Eijkemans MJ; van Rhijn BW; van der Kwast TH; Steyerberg EW
    BJU Int; 2009 Jul; 104(1):41-7. PubMed ID: 19500328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urine cytology in the follow-up of patients with transitional cell carcinoma of the urinary bladder: is that enough as a single method?
    Raica M; Miclea F; Ioiart I; Minciu R; Drăgan P
    Rom J Morphol Embryol; 1998; 44(1-4):173-8. PubMed ID: 15678859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. uCyt+ test: alternative to cystoscopy for less-invasive follow-up of patients with low risk of urothelial carcinoma.
    Lodde M; Mian C; Comploj E; Palermo S; Longhi E; Marberger M; Pycha A
    Urology; 2006 May; 67(5):950-4. PubMed ID: 16698355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.
    May M; Hakenberg OW; Gunia S; Pohling P; Helke C; Lübbe L; Nowack R; Siegsmund M; Hoschke B
    Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology.
    Skacel M; Fahmy M; Brainard JA; Pettay JD; Biscotti CV; Liou LS; Procop GW; Jones JS; Ulchaker J; Zippe CD; Tubbs RR
    J Urol; 2003 Jun; 169(6):2101-5. PubMed ID: 12771727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective evaluation of the diagnostic and potential prognostic utility of urinary human telomerase reverse transcriptase mRNA in patients with bladder cancer.
    Bowles L; Bialkowska-Hobrzanska H; Bukala B; Nott L; Razvi H
    Can J Urol; 2004 Dec; 11(6):2438-44. PubMed ID: 15636669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accuracy of the ImmunoCyt assay in the diagnosis of transitional cell carcinoma of the urinary bladder.
    Feil G; Zumbrägel A; Päulgen-Nelde HJ; Hennenlotter J; Maurer S; Krause S; Bichler KH; Stenzl A
    Anticancer Res; 2003; 23(2A):963-7. PubMed ID: 12820331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of low grade papillary bladder tumors.
    Herr HW; Donat SM; Reuter VE
    J Urol; 2007 Oct; 178(4 Pt 1):1201-5; discussion 1205. PubMed ID: 17698090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.